EC Pulmonology and Respiratory Medicine

One of the most exciting and disturbing topics in modern medicine is the growing threat of antibiotic-resistant microflora, the consensus plans to reduce the burden of which are proposed by the development of new generations of antimicrobial drugs. Such prospects are actually aimed at further development of the factor that was the cause and source of the phenomenon under discussion. At the same time, no one discusses the risk of implementing such a project, focusing only on the immediate therapeutic effect. At the same time, an analysis of the factual material on this topic shows that the role and significance of resistant microflora are clearly exaggerated, and among the consequences of long-term use of antibiotics there are those on which the nature of the assessment of the problem and the choice of ways to solve it depend.

 Keywords: Acute Pneumonia; Etiology of Pneumonia; Antibiotics; Side Effects; Antibiotic-Resistant Microflora

1. “Antimicrobial resistance” (2021).
2. Sawada T., et al. “Early detection of drug-resistant Streptococcus pneumoniae and Haemophilus influenzae by quantitative flow cytometry”. Scientific Reports 1 (2021): 2873.
3. Bankar NJ., et al. “Implementation of antimicrobial stewardship in the healthcare setting”. Cureus7 (2022): e26664.
4. Novy Gupte., et al. “Antimicrobial resistance: Negative impacts of the silent pandemic”. EC Paediatrics8 (2023): 01-04.
5. Abraham EP and Chain E. “An enzyme from bacteria able to destroy penicillin. 1940”. Reviews of Infectious Diseases 4 (1988): 677-678.
6. Rammelkamp T. “Resistance of Staphylococcus aureus to the action of penicillin”. Experimental Biology and Medicine 51 (1942): 386-389.
7. Luria SE and Delbrück M. "Mutations of bacteria from virus sensitivity to virus resistance". Genetics6 (1943): 491-511.
8. Fleming A. "The Nobel Prize in Physiology or Medicine 1945 - Penicillin: Nobel Lecture". NobelPrize.org (1945).
9. Aminov RI. "A brief history of the antibiotic era: lessons learned and challenges for the future". Frontiers in Microbiology 1 (2010): 134.
10. Gadsby NJ and Musher DM. “The microbial etiology of community-acquired pneumonia in adults: from classical bacteriology to host transcriptional signatures”. Clinical Microbiology Reviews 4 (2022): e00015-22.
11. Kyriazopoulou E., et al. “BioFire^® FilmArray^® pneumonia panel for severe lower respiratory tract infections: subgroup analysis of a randomized clinical trial”. Infectious Diseases and Therapy 3 (2021): 1437-1449.
12. Xie F., et al. “Clinical metagenomics assessments improve diagnosis and outcomes in community-acquired pneumonia”. BMC Infectious Diseases 1 (2021): 352.
13. Michael S Niederman and Antoni Torres. “Severe community-acquired pneumonia”. European Respiratory Review166 (2022): 220123.
14. Enne VI., et al. “Multicentre evaluation of two multiplex PCR platforms for the rapid microbiological investigation of nosocomial pneumonia in UK ICUs: the INHALE WP1 study”. Thorax 12 (2022): 1220-1228.
15. J Johnstone., et al. “Definitions, rates and associated mortality of ICU-acquired pneumonia: A multicenter cohort study”. Journal of Critical Care 75 (2023): 154284.
16. Lakbar I., et al. “Association between mortality and highly antimicrobial-resistant bacteria in intensive care unit-acquired pneumonia”. Scientific Reports 11 (2021): 16497.
17. Lowy FD. “Antimicrobial resistance: the example of Staphylococcus aureus”. Journal of Clinical Investigation 9 (2003): 1265-1273.
18. Walker SR. Trends and Changes in Drug Research and Development. Springer Science & Business Media (2012): 109.
19. "MRSA History Timeline: The First Half-Century, 1959-2009". The University of Chicago Medical Center (2010).
20. Kluytmans Jan., et al. “MRSA transmission in the community: emerging from under the radar”. The Lancet Infectious Diseases2 (2020): 147-149.
21. MR Millar., et al. “Carriage of antibiotic-resistant bacteria by healthy children”. Journal of Antimicrobial Chemotherapy5 (2001): 605-610.
22. CDC, Saving Lives. Protecting People. Methicillin-resistant Staphylococcus aureus (MRSA). Healthcare Settings. 24/7 (2023).
23. Albrich WC and Harbarth S. “Health-care workers: Source, vector, or victim of MRSA?” Lancet Infectious Diseases 5 (2008): 289-301.
24. Aubry-Damon H., et al. “Antimicrobial resistance in commensal flora of pig farmers”. Emerging Infectious Diseases 5 (2004): 873-879.
25. Graveland H., et al. “Methicillin resistant Staphylococcus aureus ST398 in Veal Calf Farming: Human MRSA carriage related with animal antimicrobial usage and farm hygiene”. PLoS ONE6 (2010): e10990.
26. Resolution 26 (Combating Antimicrobial Resistance and Promoting the Prudent Use of Antimicrobial Agents in Animals) of the World Assembly of Delegates of the World Organisation for Animal Health (OIE). Paris, France (2015).
27. Charles D. "Despite pledges to cut back, farms are still using antibiotics". NPR (2016).
28. Couce A and Blazquez J. “Side effects of antibiotics on genetic variability”. FEMS Microbiology Reviews 3 (2009): 531-538.
29. Joo HS., et al. “Subinhibitory concentrations of protein synthesis-inhibiting antibiotics promote in-creased expression of the agr virulence regulator and production of phenol-soluble modulin cytolysins in community-associated methicillin-resistant Staphylococcus aureus”. Antimicrobial Agents and Chemotherapy 11 (2010): 4942-4944.
30. Blázquez J., et al. “Antimicrobials as promoters of genetic variation”. Current Opinion in Microbiology 5 (2012): 561-569.
31. Clatworthy AE., et al. “Targeting virulence: a new paradigm for antimicrobial therapy”. Nature Chemical Biology 9 (2007): 541-548.
32. Rasko DA., et al. “Targeting QseC signaling and virulence for antibiotic development”. Science5892 (2008): 1078-1080.
33. Liu CI., et al. “A cholesterol biosynthesis inhibitor blocks Staphylococcus aureus virulence”. Science 5868 (2008): 1391-1394.
34. Rudan I., et al. “Epidemiology and etiology of childhood pneumonia”. Bulletin of the World Health Organization 5 (2008): 408-416.
35. WHO Revised global burden of disease 2002 estimates (2004).
36. Ruuskanen O., et al. "Viral pneumonia". Lancet9773 (2011): 1264-1275.
37. BD Huttner., et al. “COVID-19: don't neglect antimicrobial stewardship principles!”. Clinical Microbiology and Infection7 (2020): 808-810.
38. B Beovic., et al. “Antibiotic use in patients with COVID-19: a ‘snapshot’ Infectious Diseases International Research Initiative (ID-IRI) survey”. Journal of Antimicrobial Chemotherapy11 (2020): 3386-3390.
39. Rawson TM., et al. “Bacterial and fungal co-infection in individuals with coronavirus: A rapid review to support COVID-19 antimicrobial prescribing [published online ahead of print, 2020 May 2]”. Clinical Infectious Diseases 9 (2020): 2459-2468.
40. RE Leiter. “Reentry”. New England Journal of Medicine27 (2020): e141.
41. JN Rosenquist. “The Stress of Bayesian Medicine - Uncomfortable Uncertainty in the Face of Covid-19”. New England Journal of Medicine1 (2021): 7-9.
42. Salisbury H. “Helen Salisbury: What might we learn from the covid-19 pandemic?” British Medical Journal 368 (2020): m1087.
43. Oliver D. “David Oliver: Conveyor belt medicine”. British Medical Journal 368 (2020): m162.
44. C Heneghan., et al. “Differentiating viral from bacterial pneumonia”. The Centre for Evidence-Based Medicine. Evidence Service to support the COVID-19 response. University of Oxford (2020).
45. Kamat IS., et al. “Procalcitonin to distinguish viral from bacterial pneumonia: A systematic review and meta-analysis”. Clinical Infectious Diseases 3 (2020): 538-542.
46. Lhommet C., et al. “Predicting the microbial cause of community-acquired pneumonia: can physicians or a data-driven method differentiate viral from bacterial pneumonia at patient presentation?” BMC Pulmonary Medicine 1 (2020): 62.
47. Shoar S and Musher DM. “Etiology of community-acquired pneumonia in adults: a systematic review”. Pneumonia 12 (2020): 11.
48. Carlos P., et al. “CURB-65 and long-term mortality of community-acquired pneumonia: a retrospective study on hospitalized patients”. Cureus 3 (2023): e36052.
49. Palomeque A., et al. “A review of the value of point-of-care testing for community-acquired pneumonia”. Expert Review of Molecular Diagnostics 8 (2024): 729-742.
50. Cilloniz C., et al. “Pure viral sepsis secondary to community-acquired pneumonia in adults: risk and prognostic factors”. Journal of Infectious Diseases 7 (2019): 1166-1171.
51. B Ponnuthurai., et al. “Etiological and clinical profile of virus-associated community-acquired pneumonia in adults”. Chest Infections6 (2020): A55.
52. Covington EW and Rufe A. “Identification of risk factors for multidrug-resistant organisms in community-acquired bacterial pneumonia at a community hospital”. Journal of Pharmacy Practice2 (2023): 303-308.
53. Ding H., et al. “Incidence of drug-resistant pathogens in community-acquired pneumonia at a safety net hospital”. Microbiology Spectrum 8 (2024): e00792-24.
54. Sakamoto Y., et al. “In-hospital mortality associated with community-acquired pneumonia due to methicillin-resistant Staphylococcus aureus: a matched-pair cohort study”. BMC Pulmonary Medicine 1 (2021): 345.
55. C Liu and M Holubar. “Should a MRSA nasal swab guide empiric antibiotic treatment?” NEJM Evidence 12 (2022): EVIDccon2200124.
56. Peyrani P., et al. “The burden of community-acquired bacterial pneumonia in the era of antibiotic resistance”. Expert Review of Respiratory Medicine 2 (2019): 139-152.
57. Yanier Espinosa-Goire., et al. “Drug resistance microbial of Staphylococcus aureus”. Acta Scientific Medical Sciences 11 (2024): 66-70.
58. Nuzzo JB and Ledesma JR. “Why did the best prepared country in the world fare so poorly during COVID?” Journal of Economic Perspectives 4 (2023): 3-22.